Our Pricing

Understanding Wegovy and Mounjaro Equivalent Doses in the UK

Understanding Wegovy Mounjaro equivalent doses is essential for patients transitioning between these two GLP-1 receptor agonists or deciding which treatment suits their weight loss goals. While both medications work through similar mechanisms, tirzepatide (Mounjaro) and semaglutide (Wegovy) have different dosing schedules, potency levels, and monthly costs that UK patients should consider before starting treatment.

How Wegovy and Mounjaro Equivalent Doses Compare Clinically

Wegovy Mounjaro equivalent doses cannot be directly matched milligram-to-milligram because tirzepatide and semaglutide have different molecular structures and receptor binding profiles. Mounjaro acts on both GIP and GLP-1 receptors, whilst Wegovy targets only GLP-1 receptors, making direct dose equivalence comparisons challenging from a pharmacological perspective [1].

Clinical trials suggest that Mounjaro 5mg may produce similar weight loss outcomes to Wegovy 1.7mg, whilst Mounjaro 10mg and 15mg doses typically exceed Wegovy's maximum 2.4mg dose in terms of average weight reduction [2]. The SURPASS-2 head-to-head trial demonstrated that tirzepatide 10mg and 15mg resulted in greater weight loss compared to semaglutide 1mg in patients with type 2 diabetes, though direct Wegovy comparisons in obesity populations are still emerging [3].

UK prescribers assess individual patient factors including BMI, comorbidities, previous treatment response, and tolerability when determining appropriate starting doses. Both medications require gradual dose escalation over 16-20 weeks to minimise gastrointestinal side effects, and treatment must be prescribed following clinical assessment by a UK-registered prescriber.

Wegovy Mounjaro Equivalent Doses: Monthly Cost Breakdown UK

The monthly cost of Wegovy Mounjaro equivalent doses varies significantly across UK pharmacies, with Cured Pharmacy offering Mounjaro from £124.99 per month and Wegovy from £124.99 per month, subject to prescriber approval. New patients can Save £20 off their first order using code Weightlossnew, making these treatments more accessible for long-term weight management programmes.

Maintenance doses represent the most significant cost consideration. Wegovy's maximum maintenance dose of 2.4mg weekly costs from £124.99 monthly at Cured Pharmacy, whilst Mounjaro's maintenance doses of 10mg or 15mg weekly cost from £124.99 monthly. Patients should factor in the dose escalation period, which spans approximately four months for both medications before reaching maintenance dosing.

Cost-Effectiveness of Wegovy Mounjaro Equivalent Doses

When evaluating cost-effectiveness of Wegovy Mounjaro equivalent doses, UK patients should consider average weight loss outcomes relative to monthly investment. STEP trial data showed Wegovy 2.4mg produced an average 14.9% body weight reduction over 68 weeks, whilst SURMOUNT-1 trial data demonstrated Mounjaro 15mg achieved an average 20.9% weight reduction over 72 weeks [4]. Both treatments require ongoing administration to maintain weight loss, making long-term affordability a crucial consideration.

Cured Pharmacy's transparent upfront pricing allows patients to calculate total treatment costs before completing their clinical assessment. All prescription weight loss medications available through Cured Pharmacy require online consultation with a UK-registered prescriber, ensuring appropriate patient selection and ongoing monitoring throughout treatment.

Dose Escalation Schedules for Wegovy Mounjaro Equivalent Doses

Understanding the dose escalation schedule is critical when comparing Wegovy Mounjaro equivalent doses, as both medications require gradual titration to therapeutic levels. Wegovy follows a five-step escalation: 0.25mg weekly for four weeks, 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, then 2.4mg maintenance dose. This 16-week titration minimises nausea, vomiting, and diarrhoea that commonly occur with rapid GLP-1 receptor agonist initiation [5].

Mounjaro employs a similar cautious approach, starting at 2.5mg weekly for four weeks, then increasing to 5mg, 7.5mg, 10mg, and potentially 15mg at four-week intervals based on tolerability and weight loss response. The extended escalation period allows patients to adapt to increasing GLP-1 and GIP receptor stimulation whilst UK prescribers monitor for adverse effects and treatment efficacy.

Adjusting Between Wegovy Mounjaro Equivalent Doses

Patients considering switching between Wegovy and Mounjaro should consult their UK prescriber regarding appropriate equivalent starting doses. There is no established conversion protocol, so prescribers typically restart the dose escalation schedule when transitioning between these medications. This conservative approach prioritises patient safety and tolerability over immediate therapeutic dosing.

Clinical experience suggests patients tolerating Wegovy 2.4mg may begin Mounjaro at 5mg rather than 2.5mg, potentially shortening the escalation period. However, individual tolerability varies considerably, and some patients may require the full titration schedule despite previous GLP-1 receptor agonist exposure. All dosing decisions must be made by a qualified UK prescriber following thorough clinical assessment.

Comparing Efficacy Across Wegovy Mounjaro Equivalent Doses

Clinical trial data provides valuable insight when evaluating Wegovy Mounjaro equivalent doses for weight loss efficacy. The STEP 1 trial demonstrated that Wegovy 2.4mg produced an average 14.9% body weight reduction compared to 2.4% with placebo over 68 weeks in adults with obesity [4]. Participants also experienced improvements in cardiovascular risk factors including blood pressure, lipid profiles, and glycaemic control.

SURMOUNT-1 trial results showed Mounjaro produced dose-dependent weight loss, with 15mg achieving an average 20.9% reduction, 10mg achieving 19.5%, and 5mg achieving 15.0% over 72 weeks [4]. These outcomes suggest higher Mounjaro doses may exceed Wegovy's maximum dose in terms of average weight reduction, though individual responses vary considerably based on adherence, lifestyle modifications, and metabolic factors.

Side Effect Profiles of Wegovy Mounjaro Equivalent Doses

Both Wegovy and Mounjaro share similar side effect profiles due to their GLP-1 receptor agonist mechanisms, with gastrointestinal symptoms representing the most common adverse effects. Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort occur in 30-50% of patients during dose escalation, though symptoms typically diminish with continued treatment [6].

Mounjaro's dual GIP/GLP-1 receptor agonism may produce slightly different tolerability compared to Wegovy's selective GLP-1 action, though head-to-head safety data in obesity populations remains limited. UK prescribers monitor patients throughout treatment escalation, adjusting doses or extending titration schedules when side effects limit tolerability. Serious adverse effects including pancreatitis, gallbladder disease, and hypoglycaemia (particularly in diabetic patients) require immediate medical attention.

Patients receiving Wegovy Mounjaro equivalent doses through Cured Pharmacy undergo clinical assessment by UK-registered prescribers who evaluate contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Ongoing monitoring ensures early detection of adverse effects and appropriate treatment adjustments.

Accessing Wegovy Mounjaro Equivalent Doses Through Cured Pharmacy

Cured Pharmacy offers convenient access to Wegovy Mounjaro equivalent doses through a streamlined online clinical assessment process that takes under three minutes to complete. UK-registered prescribers review each patient's medical history, current medications, weight loss goals, and contraindications before approving treatment. This ensures appropriate patient selection whilst maintaining the convenience of online healthcare access.

All medications dispensed by Cured Pharmacy are genuine UK-licensed products sourced through regulated pharmaceutical supply chains. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees clinical governance and medication safety protocols, ensuring compliance with MHRA and GPhC standards. Discreet packaging protects patient privacy, whilst transparent upfront pricing eliminates unexpected costs during the consultation process.

Patients approved for treatment receive their first prescription with clear dosing instructions, injection technique guidance, and information about expected side effects. Ongoing prescriptions require follow-up assessments to monitor weight loss progress, tolerability, and any emerging health concerns. Cured Pharmacy's UK-registered clinical team remains available to address patient questions throughout treatment, providing expert support for safe and effective weight management.

Next Steps for Starting Wegovy or Mounjaro

Patients interested in accessing Wegovy Mounjaro equivalent doses should begin by completing the online clinical assessment at Cured Pharmacy. The assessment gathers essential medical information including BMI, previous weight loss attempts, comorbid conditions, and current medications. UK prescribers review submissions individually, approving treatment only when clinically appropriate and safe.

New patients can Save £20 off their first order using code Weightlossnew, reducing the initial cost barrier to accessing these effective weight loss treatments. Treatment typically arrives within 1-2 working days via discreet courier, allowing patients to begin their weight loss journey quickly following prescriber approval. Long-term success requires combining medication with sustainable dietary modifications and increased physical activity, as recommended by NICE guidelines for obesity management [7].

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 15 August 2026]
4. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
6. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.